Citicoline data

University researchers presented complete findings from a Phase III trial with citicoline in 259 stroke patients at the American Academy of Neurology meeting in San Francisco. The rate of improvement of treated patients was significantly faster than for those on placebo (p<0.02). Those who received 500 mg/day achieved complete or near-complete recovery two weeks faster than those on placebo (for initial results, see BioCentury, Feb. 26).

More patients in the 500 mg and 2,000 mg groups showed normal or near-normal scores in mental function (p<0.04), as measured by the Mini-Mental State Exam, which grades the cognitive state of patients. Patients in those two dose groups also had significantly greater improvement in neurologic function, the primary end point as measured by the Barthel Index, than placebo patients at week 12 (p<0.05). ...